Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Influence of County Sampling on Past Estimates of Latent Tuberculosis Infection Prevalence.

Haddad MB, Raz KM, Hill AN, Navin TR, Castro KG, Winston CA, Gandhi NR, Lash TL.

Ann Am Thorac Soc. 2019 Mar 19. doi: 10.1513/AnnalsATS.201901-062RL. [Epub ahead of print] No abstract available.

PMID:
30888833
2.

Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.

Wasserman S, Denti P, Brust JCM, Abdelwahab M, Hlungulu S, Wiesner L, Norman J, Sirgel FA, Warren RM, Esmail A, Dheda K, Gandhi NR, Meintjes G, Maartens G.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02164-18. doi: 10.1128/AAC.02164-18. Print 2019 Mar.

PMID:
30617089
3.

Causal inference with multiple concurrent medications: A comparison of methods and an application in multidrug-resistant tuberculosis.

Siddique AA, Schnitzer ME, Bahamyirou A, Wang G, Holtz TH, Migliori GB, Sotgiu G, Gandhi NR, Vargas MH, Menzies D, Benedetti A.

Stat Methods Med Res. 2018 Oct 31:962280218808817. doi: 10.1177/0962280218808817. [Epub ahead of print]

PMID:
30381005
4.

A new era for treatment of drug-resistant tuberculosis.

Gandhi NR, Brust JCM, Shah NS.

Eur Respir J. 2018 Oct 4;52(4). pii: 1801350. doi: 10.1183/13993003.01350-2018. Print 2018 Oct. No abstract available.

PMID:
30287493
5.

Closing the book on Category II: time for individualized regimens for patients with recurrent tuberculosis.

Auld SC, Gandhi NR, Shah NS.

Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1113-1114. doi: 10.5588/ijtld.18.0569. No abstract available.

PMID:
30236175
6.

Simple Estimates for Local Prevalence of Latent Tuberculosis Infection, United States, 2011-2015.

Haddad MB, Raz KM, Lash TL, Hill AN, Kammerer JS, Winston CA, Castro KG, Gandhi NR, Navin TR.

Emerg Infect Dis. 2018 Oct;24(10):1930-1933. doi: 10.3201/eid2410.180716.

7.

Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection.

Rentsch CT, Cartwright EJ, Gandhi NR, Brown ST, Rodriguez-Barradas MC, Goetz MB, Marconi VC, Gibert CL, Re VL 3rd, Fiellin DA, Justice AC, Tate JP.

Ann Epidemiol. 2018 Nov;28(11):808-811. doi: 10.1016/j.annepidem.2018.08.007. Epub 2018 Aug 23.

8.

Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities.

Auld SC, Shah NS, Mathema B, Brown TS, Ismail N, Omar SV, Brust JCM, Nelson KN, Allana S, Campbell A, Mlisana K, Moodley P, Gandhi NR.

Eur Respir J. 2018 Oct 18;52(4). pii: 1800246. doi: 10.1183/13993003.00246-2018. Print 2018 Oct.

PMID:
30115614
9.

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR Jr.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00770-18. doi: 10.1128/AAC.00770-18. Print 2018 Oct.

PMID:
30012767
10.

Spatial Patterns of Extensively Drug-Resistant Tuberculosis Transmission in KwaZulu-Natal, South Africa.

Nelson KN, Shah NS, Mathema B, Ismail N, Brust JCM, Brown TS, Auld SC, Omar SV, Morris N, Campbell A, Allana S, Moodley P, Mlisana K, Gandhi NR.

J Infect Dis. 2018 Nov 5;218(12):1964-1973. doi: 10.1093/infdis/jiy394.

PMID:
29961879
11.

Use of Multiple Imputation to Estimate the Proportion of Respiratory Virus Detections Among Patients Hospitalized With Community-Acquired Pneumonia.

Bozio CH, Flanders WD, Finelli L, Bramley AM, Reed C, Gandhi NR, Vidal JE, Erdman D, Levine MZ, Lindstrom S, Ampofo K, Arnold SR, Self WH, Williams DJ, Grijalva CG, Anderson EJ, McCullers JA, Edwards KM, Pavia AT, Wunderink RG, Jain S.

Open Forum Infect Dis. 2018 Mar 16;5(4):ofy061. doi: 10.1093/ofid/ofy061. eCollection 2018 Apr.

12.

Where is tuberculosis transmission happening? Insights from the literature, new tools to study transmission and implications for the elimination of tuberculosis.

Auld SC, Shah NS, Cohen T, Martinson NA, Gandhi NR.

Respirology. 2018 Jun 5. doi: 10.1111/resp.13333. [Epub ahead of print] Review.

13.

A dual purpose for household contact investigations: preventing TB disease and improving diabetes outcomes.

Magee MJ, Gandhi NR, Kornfeld H.

Int J Tuberc Lung Dis. 2018 Jun 1;22(6):594-595. doi: 10.5588/ijtld.18.0262. No abstract available.

PMID:
29862941
14.

A High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in Human Mycobacterium tuberculosis Infection.

Whatney WE, Gandhi NR, Lindestam Arlehamn CS, Nizam A, Wu H, Quezada MJ, Campbell A, Allana S, Kabongo MM, Khayumbi J, Muchiri B, Ongalo J, Tonui J, Sasser LE, Fergus TJ, Ouma GS, Ouma SG, Beck AA, Mulligan MJ, Oladele A, Kaushal D, Cain KP, Waller L, Blumberg HM, Altman JD, Ernst JD, Rengarajan J, Day CL; TBRU-ASTRa Study Group.

J Immunol. 2018 Apr 15;200(8):3008-3019. doi: 10.4049/jimmunol.1701737. Epub 2018 Mar 14.

PMID:
29540577
15.

Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa.

Brust JCM, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, Johnson BA, Master I, Mthiyane T, Lachman S, Larkan LM, Ning Y, Malik A, Smith JP, Gandhi NR.

Clin Infect Dis. 2018 Apr 3;66(8):1246-1253. doi: 10.1093/cid/cix1125.

PMID:
29293906
16.

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr.

Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.

17.

Tuberculosis Infectiousness and Host Susceptibility.

Turner RD, Chiu C, Churchyard GJ, Esmail H, Lewinsohn DM, Gandhi NR, Fennelly KP.

J Infect Dis. 2017 Nov 3;216(suppl_6):S636-S643. doi: 10.1093/infdis/jix361. Review.

18.

Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?

Auld SC, Kasmar AG, Dowdy DW, Mathema B, Gandhi NR, Churchyard GJ, Rustomjee R, Shah NS.

J Infect Dis. 2017 Nov 3;216(suppl_6):S662-S668. doi: 10.1093/infdis/jix353. Review.

19.

Spatial distribution of extensively drug-resistant tuberculosis (XDR TB) patients in KwaZulu-Natal, South Africa.

Kapwata T, Morris N, Campbell A, Mthiyane T, Mpangase P, Nelson KN, Allana S, Brust JCM, Moodley P, Mlisana K, Gandhi NR, Shah NS.

PLoS One. 2017 Oct 13;12(10):e0181797. doi: 10.1371/journal.pone.0181797. eCollection 2017.

20.

Polymorphisms in the vitamin D receptor gene are associated with reduced rate of sputum culture conversion in multidrug-resistant tuberculosis patients in South Africa.

Magee MJ, Sun YV, Brust JCM, Shah NS, Ning Y, Allana S, Campbell A, Hui Q, Mlisana K, Moodley P, Gandhi NR.

PLoS One. 2017 Jul 10;12(7):e0180916. doi: 10.1371/journal.pone.0180916. eCollection 2017.

21.

Impact of gyrB and eis Mutations in Improving Detection of Second-Line-Drug Resistance among Mycobacterium tuberculosis Isolates from Georgia.

Bablishvili N, Tukvadze N, Shashkina E, Mathema B, Gandhi NR, Blumberg HM, Kempker RR.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01921-16. doi: 10.1128/AAC.01921-16. Print 2017 Sep.

22.

Sociodemographic and Clinical Risk Factors Associated With Tuberculosis Mortality in the United States, 2009-2013.

Hannah HA, Miramontes R, Gandhi NR.

Public Health Rep. 2017 May/Jun;132(3):366-375. doi: 10.1177/0033354917698117. Epub 2017 Apr 10.

23.

pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia.

Allana S, Shashkina E, Mathema B, Bablishvili N, Tukvadze N, Shah NS, Kempker RR, Blumberg HM, Moodley P, Mlisana K, Brust JC, Gandhi NR.

Emerg Infect Dis. 2017 Mar;23(3):491-495. doi: 10.3201/eid2303.161034.

24.

Transmission of Extensively Drug-Resistant Tuberculosis in South Africa.

Shah NS, Auld SC, Brust JC, Mathema B, Ismail N, Moodley P, Mlisana K, Allana S, Campbell A, Mthiyane T, Morris N, Mpangase P, van der Meulen H, Omar SV, Brown TS, Narechania A, Shaskina E, Kapwata T, Kreiswirth B, Gandhi NR.

N Engl J Med. 2017 Jan 19;376(3):243-253. doi: 10.1056/NEJMoa1604544.

25.

More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.

Brust JC, Shah NS, Gandhi NR.

N Engl J Med. 2016 Dec 29;375(26):2610. doi: 10.1056/NEJMc1613123. No abstract available.

26.

IFN-γ Release Assay Result Is Associated with Disease Site and Death in Active Tuberculosis.

Auld SC, Lee SH, Click ES, Miramontes R, Day CL, Gandhi NR, Heilig CM.

Ann Am Thorac Soc. 2016 Dec;13(12):2151-2158.

27.

Diabetes Reduces the Rate of Sputum Culture Conversion in Patients With Newly Diagnosed Multidrug-Resistant Tuberculosis.

Salindri AD, Kipiani M, Kempker RR, Gandhi NR, Darchia L, Tukvadze N, Blumberg HM, Magee MJ.

Open Forum Infect Dis. 2016 Jun 16;3(3):ofw126. doi: 10.1093/ofid/ofw126. eCollection 2016 Sep.

28.

Diabetes mellitus and extrapulmonary tuberculosis: site distribution and risk of mortality.

Magee MJ, Foote M, Ray SM, Gandhi NR, Kempker RR.

Epidemiol Infect. 2016 Jul;144(10):2209-16. doi: 10.1017/S0950268816000364. Epub 2016 Mar 1.

29.

Reply: Missing Stowaways and Lack of Expected Concurrent Infections.

Interrante JD, Haddad MB, Kim L, Gandhi NR.

Ann Am Thorac Soc. 2015 Dec;12(12):1898-9. doi: 10.1513/AnnalsATS.201509-651LE. No abstract available.

30.

High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.

Niehaus AJ, Mlisana K, Gandhi NR, Mathema B, Brust JC.

PLoS One. 2015 Sep 2;10(9):e0135003. doi: 10.1371/journal.pone.0135003. eCollection 2015.

31.

Exogenous Reinfection as a Cause of Late Recurrent Tuberculosis in the United States.

Interrante JD, Haddad MB, Kim L, Gandhi NR.

Ann Am Thorac Soc. 2015 Nov;12(11):1619-26. doi: 10.1513/AnnalsATS.201507-429OC.

32.

Incidence and Geographic Distribution of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa.

Lim JR, Gandhi NR, Mthiyane T, Mlisana K, Moodley J, Jaglal P, Ramdin N, Brust JC, Ismail N, Rustomjee R, Shah NS.

PLoS One. 2015 Jul 6;10(7):e0132076. doi: 10.1371/journal.pone.0132076. eCollection 2015.

33.

Diabetes mellitus is associated with cavities, smear grade, and multidrug-resistant tuberculosis in Georgia.

Magee MJ, Kempker RR, Kipiani M, Gandhi NR, Darchia L, Tukvadze N, Howards PP, Narayan KM, Blumberg HM.

Int J Tuberc Lung Dis. 2015 Jun;19(6):685-92. doi: 10.5588/ijtld.14.0811.

34.

Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy.

Viswanathan S, Justice AC, Alexander GC, Brown TT, Gandhi NR, McNicholl IR, Rimland D, Rodriguez-Barradas MC, Jacobson LP.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):493-8. doi: 10.1097/QAI.0000000000000643.

35.

Reduced virulence of an extensively drug-resistant outbreak strain of Mycobacterium tuberculosis in a murine model.

Smith KL, Saini D, Bardarov S, Larsen M, Frothingham R, Gandhi NR, Jacobs WR Jr, Sturm AW, Lee S.

PLoS One. 2014 Apr 14;9(4):e94953. doi: 10.1371/journal.pone.0094953. eCollection 2014.

36.

Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.

Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R.

Lancet Respir Med. 2014 Apr;2(4):321-38. doi: 10.1016/S2213-2600(14)70031-1. Epub 2014 Mar 24. Review.

37.

Minimal diversity of drug-resistant Mycobacterium tuberculosis strains, South Africa.

Gandhi NR, Brust JC, Moodley P, Weissman D, Heo M, Ning Y, Moll AP, Friedland GH, Sturm AW, Shah NS.

Emerg Infect Dis. 2014 Mar;20(3):426-33. doi: 10.3201/eid2003.131083.

38.

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.

IeDEA and ART Cohort Collaborations, Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, Nash D, Gsponer T, Sungkanuparph S, McGowan C, May M, Cooper D, Chimbetete C, Wolff M, Collier A, McManus H, Davies MA, Costagliola D, Crabtree-Ramirez B, Chaiwarith R, Cescon A, Cornell M, Diero L, Phanuphak P, Sawadogo A, Ehmer J, Eholie SP, Li PC, Fox MP, Gandhi NR, González E, Lee CK, Hoffmann CJ, Kambugu A, Keiser O, Ditangco R, Prozesky H, Lampe F, Kumarasamy N, Kitahata M, Lugina E, Lyamuya R, Vonthanak S, Fink V, d'Arminio Monforte A, Luz PM, Chen YM, Minga A, Casabona J, Mwango A, Choi JY, Newell ML, Bukusi EA, Ngonyani K, Merati TP, Otieno J, Bosco MB, Phiri S, Ng OT, Anastos K, Rockstroh J, Santos I, Oka S, Somi G, Stephan C, Teira R, Wabwire D, Wandeler G, Boulle A, Reiss P, Wood R, Chi BH, Williams C, Sterne JA, Egger M.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e8-16. doi: 10.1097/QAI.0b013e3182a39979.

39.

Chest radiograph findings and time to culture conversion in patients with multidrug-resistant tuberculosis and HIV in Tugela Ferry, South Africa.

Brust JC, Berman AR, Zalta B, Haramati LB, Ning Y, Heo M, van der Merwe TL, Bamber S, Moll AP, Friedland GH, Shah NS, Gandhi NR.

PLoS One. 2013 Sep 6;8(9):e73975. doi: 10.1371/journal.pone.0073975. eCollection 2013.

40.

Validation of an algorithm to identify antiretroviral-naïve status at time of entry into a large, observational cohort of HIV-infected patients.

Gandhi NR, Tate JP, Rodriguez-Barradas MC, Rimland D, Goetz MB, Gibert C, Brown ST, Mattocks K, Justice AC.

Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):1019-25. doi: 10.1002/pds.3476. Epub 2013 Jul 9.

41.

Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa.

Brust JC, Shah NS, van der Merwe TL, Bamber S, Ning Y, Heo M, Moll AP, Loveday M, Lalloo UG, Friedland GH, Gandhi NR.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):436-40. doi: 10.1097/QAI.0b013e31828175ed.

42.

Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa.

Gandhi NR, Weissman D, Moodley P, Ramathal M, Elson I, Kreiswirth BN, Mathema B, Shashkina E, Rothenberg R, Moll AP, Friedland G, Sturm AW, Shah NS.

J Infect Dis. 2013 Jan 1;207(1):9-17. doi: 10.1093/infdis/jis631. Epub 2012 Nov 19.

43.

Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.

Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, Hollm-Delgado MG, Palmero D, Pérez-Guzmán C, Vargas MH, D'Ambrosio L, Spanevello A, Bauer M, Chan ED, Schaaf HS, Keshavjee S, Holtz TH, Menzies D; “The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB”.

Eur Respir J. 2013 Jul;42(1):169-179. doi: 10.1183/09031936.00136312. Epub 2012 Oct 11.

44.

Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care.

Brust JC, Shah NS, Scott M, Chaiyachati K, Lygizos M, van der Merwe TL, Bamber S, Radebe Z, Loveday M, Moll AP, Margot B, Lalloo UG, Friedland GH, Gandhi NR.

Int J Tuberc Lung Dis. 2012 Aug;16(8):998-1004. doi: 10.5588/ijtld.11.0713. Epub 2012 Jun 5.

45.

Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting.

Gandhi NR, Andrews JR, Brust JC, Montreuil R, Weissman D, Heo M, Moll AP, Friedland GH, Shah NS.

Int J Tuberc Lung Dis. 2012 Jan;16(1):90-7. doi: 10.5588/ijtld.11.0153.

46.

Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting.

Vella V, Racalbuto V, Guerra R, Marra C, Moll A, Mhlanga Z, Maluleke M, Mhlope H, Margot B, Friedland G, Shah NS, Gandhi NR.

Int J Tuberc Lung Dis. 2011 Sep;15(9):1170-5, i. doi: 10.5588/ijtld.10.0781.

PMID:
21943840
47.

Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa.

Shah NS, Richardson J, Moodley P, Moodley S, Babaria P, Ramtahal M, Heysell SK, Li X, Moll AP, Friedland G, Sturm AW, Gandhi NR.

Emerg Infect Dis. 2011 Mar;17(3):510-3. doi: 10.3201/eid1703.101363.

48.

Rapid diagnosis of tuberculosis and multidrug resistance by the microscopic-observation drug-susceptibility assay.

Shah NS, Moodley P, Babaria P, Moodley S, Ramtahal M, Richardson J, Heysell S, Li X, Moll A, Friedland G, Sturm AW, Gandhi NR.

Am J Respir Crit Care Med. 2011 May 15;183(10):1427-33. doi: 10.1164/rccm.201009-1449OC. Epub 2011 Feb 4.

PMID:
21297071
49.

Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa.

Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, Li X, Loveday M, Bamber SA, Lalloo UG, Friedland GH, Shah NS, Gandhi NR.

PLoS One. 2011 Jan 6;6(1):e15841. doi: 10.1371/journal.pone.0015841.

50.

Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community.

Andrews JR, Shah NS, Weissman D, Moll AP, Friedland G, Gandhi NR.

PLoS One. 2010 Dec 29;5(12):e15735. doi: 10.1371/journal.pone.0015735.

Supplemental Content

Loading ...
Support Center